Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in ...

Exsilio Therapeutics CEO and OrbiMed partner Tal Zaks on how he shows investors the value path for cutting-edge research.

Managing clinical trial disclosures can be tedious and error-prone, opening the door to noncompliance. TrialScope Disclose provides a better way. Our centralized platform automates data entry and ...

Terran Biosciences' founder and CEO Sam Clark talks about big opportunities for prodrug development in 2025, the importance of a strong medicinal chemistry team, and a potential increase in M&A ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

It was to “embrace diversity.” I learned this sage piece of advice from my grandmother who traveled from Scotland on her own across the Atlantic at a young age to make her way in the land of ...

Chris Garabedian, CEO of Xontogeny, a life science accelerator, discusses what other events provide value during the annual J.P. Morgan Healthcare conference (JPM), such as the Biotech Showcase. The ...

In this executive virtual roundtable (EVR) section, Tim Valko, head of global manufacturing supply chain, Atara Biotherapeutics, discusses the economic challenges surrounding cell therapy ...

AI and ML marry computational science to biology, creating new opportunities for biotech.

A | REPRESENTING THE INVESTOR WHILE KEEPING THE DIRECTOR HAT ON CAN BECOME A SOURCE OF CONFLICTING PRIORITIES. As a public company board member, the interest of all shareholders takes priority over ...

Coming into the election cycle, the political environment may have a major impact on the biopharma industry in the near term. The capital markets have a difficulty operating in volatile times because ...